Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: BMY — Bristol Myers Squibb's more consistent earnings momentum, raised full-year guidance, and double-digit Growth Portfolio expansion give it a relative edge over PFE.
- Bristol Myers Squibb reported third-quarter revenue of $13.07 billion (up 7% year over year) and raised its full-year 2026 revenue outlook, while its Growth Portfolio grew 12%.
- Pfizer has rebounded roughly 20% year to date and recently touched a 52-week high, but recent quarters were pressured by non-cash write-downs and sharply declining COVID-19 product sales.
- Both companies face patent expirations (loss of exclusivity) on key products, including the shared blood thinner Eliquis, making pipeline execution central to each story.
- Pfizer offers a higher dividend yield of roughly 5.8%, while Bristol Myers Squibb carries a yield near 4% with a lower forward valuation and stronger recent free cash flow relative to earnings.
- For deeper coverage, explore BMY Major News and BMY Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- To see how AI-powered strategies are trading these and other tickers, explore the curated Trending AI Robots section.
Introduction
Bristol Myers Squibb and Pfizer are two of the largest pharmaceutical companies in the world, and their stock comparison is especially relevant today because both face the same structural challenge: navigating patent expirations while trying to grow newer therapies fast enough to offset declining legacy sales. This comparison is relevant for income-focused investors drawn to their above-average dividend yields, as well as for growth-minded traders evaluating which company has stronger pipeline momentum and relative performance. The two firms are also directly linked through a long-standing collaboration on the blockbuster blood thinner Eliquis, meaning their fundamentals and market positioning are intertwined. Understanding how their recent performance, catalysts, and risk profiles diverge can help investors assess which name offers the more compelling risk-adjusted setup in the current environment.
BMY Overview and Recent Performance
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, cardiovascular disease, and immunology. In recent weeks, the company delivered third-quarter results that exceeded expectations, reporting revenue of $13.07 billion, up 7% year over year, and adjusted earnings per share (EPS, a measure of profit divided by shares outstanding) that topped analyst forecasts. Management also raised its full-year 2026 revenue guidance, reflecting confidence in its outlook.
A key driver has been the Growth Portfolio, which rose 12% year over year on strength from drugs such as Breyanzi, Reblozyl, Camzyos, and Opdivo Qvantig. This newer portfolio now accounts for the majority of total revenue, helping offset ongoing generic erosion in the Legacy Portfolio from products like Revlimid and Pomalyst. Eliquis, co-marketed with Pfizer, grew 25% and remains the company's top revenue generator. Shares have gained roughly 17% to 19% year to date, outpacing the broader market, and the stock trades at a relatively low forward valuation while supporting a dividend that has been raised for 17 consecutive years.
PFE Overview and Recent Performance
Pfizer is a diversified pharmaceutical and biotechnology company with franchises spanning oncology, vaccines, immunology, cardiovascular disease, and infectious diseases. Its market positioning has been reshaped by large acquisitions, including Seagen in oncology and Metsera in the obesity space. In recent market activity, Pfizer's shares have climbed roughly 20% year to date and recently reached a 52-week high, reflecting improving sentiment around the company's turnaround and cost-reduction efforts.
However, the fundamental picture is mixed. Sales of Pfizer's COVID-19 products, Comirnaty and Paxlovid, have continued to decline sharply, and a recent quarter produced a net loss driven by roughly $4.3 billion in non-cash write-downs tied to intangible assets. Management has emphasized progress on cost savings — removing about $7.2 billion from its cost base over three years and announcing further reductions — along with new-product growth running in the double digits. Pfizer's dividend yield of roughly 5.8% is among the highest in large-cap pharma, backed by 352 consecutive quarterly dividend payments, though recent net income has at times fallen below the amount paid out in dividends.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of algorithmic trading bots from a much larger universe of hundreds of available AI Trading Bots, which collectively trade thousands of different tickers across the market. Because not every bot suits every market condition, only the strongest and most relevant strategies are featured in this section at any given time. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and basket of tickers, allowing users to compare approaches ranging from short-term momentum to longer-horizon trend following. The page highlights key metrics so traders can assess which automated strategies are currently performing well. To explore which AI-driven strategies are positioned for today's conditions, visit the Trending AI Robots page.
Head-to-Head Comparison
While both companies operate in the same industry, their market positioning and risk profiles differ in important ways. Bristol Myers Squibb has shown more consistent near-term execution, with its Growth Portfolio already contributing a majority of revenue and delivering double-digit expansion, whereas Pfizer is still in an earlier phase of its turnaround as newer acquired products ramp up. On the other hand, Pfizer's broader diversification — including vaccines and a growing oncology franchise built through Seagen — provides multiple avenues for growth, while its higher dividend yield reflects both income appeal and a market discount for its patent-expiration risk.
Recent momentum also diverges beneath the surface. Bristol Myers Squibb has repeatedly beaten earnings expectations and raised guidance, whereas Pfizer has beaten consensus in recent quarters but recorded net losses from write-downs that complicate the earnings picture. Valuation differs as well: Bristol Myers Squibb trades below roughly 10 times forward earnings, while Pfizer's trailing price-to-earnings ratio is elevated due to reduced reported profits, even though its forward multiple remains low. Both names carry concentration risk around Eliquis and face generic competition, so relative performance ultimately hinges on which pipeline can more quickly replace declining legacy revenue.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor BMY over PFE. Bristol Myers Squibb demonstrates more consistent trend consistency in its fundamentals, with sustained double-digit Growth Portfolio expansion, repeated earnings beats, and upward guidance revisions providing steadier catalysts. Pfizer's recovery is real but still transitional, with non-cash write-downs and the rapid unwind of COVID-related revenue introducing more variability into its results. While Pfizer's higher yield and improving sentiment are notable, Bristol Myers Squibb's stronger combination of relative earnings momentum, free cash flow, and lower forward valuation gives it a modestly more favorable positioning. This assessment reflects a probabilistic, data-driven view of current conditions rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and PFE is a Hold.
BMY's Indicator enters downward trend
The Aroon Indicator for BMY entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 103 of the 186 cases the stock moved lower. This puts the odds of a downward move at 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 68 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 13 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 49 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 25 of 49 cases over the following month. The odds of a continued upward trend are 51%.
BMY moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly worse than average.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.360). P/E Ratio (13.627) is within average values for comparable stocks, (21.695). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
PFE sees MACD Histogram crosses below signal line
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 30 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 195 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.360). P/E Ratio (38.169) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 100 | |
SMR RATING 1..100 | 22 | 83 | |
PRICE GROWTH RATING 1..100 | 42 | 21 | |
P/E GROWTH RATING 1..100 | 60 | 4 | |
SEASONALITY SCORE 1..100 | 65 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (96) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's Profit vs Risk Rating (66) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as BMY (42). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
PFE's P/E Growth Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (60). This means that PFE’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 43% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 54% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 48% |
| Advances ODDS (%) | 6 days ago 56% | 6 days ago 54% |
| Declines ODDS (%) | 1 day ago 55% | 1 day ago 56% |
| BollingerBands ODDS (%) | 1 day ago 45% | N/A |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 2 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.54% price change this week, while PFE (@Pharmaceuticals: Major) price change was -2.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
BMY is expected to report earnings on Feb 04, 2027.
PFE is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.20% | ||
| BMY - PFE | 60% Loosely correlated | -1.57% | ||
| AMGN - PFE | 53% Loosely correlated | +0.03% | ||
| GSK - PFE | 51% Loosely correlated | -0.16% | ||
| NVS - PFE | 50% Loosely correlated | +0.38% | ||
| BIIB - PFE | 46% Loosely correlated | +1.81% | ||
More | ||||